Paper8954169
Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
Schwendener RA and 1 other. J Cancer Res Clin Oncol, 1996. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. Papers, record 8954169. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8954169
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimetabolites, Antineoplastic | Major topic |
| Cytarabine | Major topic |
| Leukemia L1210 | Major topic |
| Administration, Oral | |
| Animals | |
| Female | |
| Infusions, Parenteral | |
| Liposomes | |
| Mice | |
| Mice, Inbred Strains | |
| Neoplasm Transplantation | |
| Structure-Activity Relationship |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3719896 | Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3719896 | PubMed |
| 2 | 7554036 | Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7554036 | PubMed |
| 3 | 8836110 | Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates. | Anticancer Drug Des | 1996 | https://conductscience.org/library/papers/8836110 | PubMed |
| 4 | 5289712 | Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. | Clin Pharmacol Ther | 1971 | https://conductscience.org/library/papers/5289712 | PubMed |
| 5 | 8576276 | Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine. | J Cancer Res Clin Oncol | 1996 | https://conductscience.org/library/papers/8576276 | PubMed |
| 6 | 7554040 | Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7554040 | PubMed |
| 7 | 7577448 | Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7577448 | PubMed |
| 8 | 7596174 | Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. | Leukemia | 1995 | https://conductscience.org/library/papers/7596174 | PubMed |
| 9 | 7734320 | Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7734320 | PubMed |
| 10 | 1749580 | Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate. | Oncology | 1991 | https://conductscience.org/library/papers/1749580 | PubMed |
| 11 | 2507491 | Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine. | Jpn J Cancer Res | 1989 | https://conductscience.org/library/papers/2507491 | PubMed |
| 12 | 3941019 | Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. | Int J Cancer | 1986 | https://conductscience.org/library/papers/3941019 | PubMed |
| 13 | 7791024 | Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. | J Pharm Pharmacol | 1995 | https://conductscience.org/library/papers/7791024 | PubMed |
| 14 | 7057424 | Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs. | J Med Chem | 1982 | https://conductscience.org/library/papers/7057424 | PubMed |
| 15 | 1592536 | Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine. | Int J Cancer | 1992 | https://conductscience.org/library/papers/1592536 | PubMed |
| 16 | 8261429 | Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. | Cancer Res | 1994 | https://conductscience.org/library/papers/8261429 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34399200 | Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/34399200 | PubMed |
| 28123991 | Enhanced bioavailability of danazol nanosuspensions by wet milling and high-pressure homogenization. | Int J Pharm Investig | 2016 | https://conductscience.org/library/papers/28123991 | PubMed |
| 24459591 | Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. | ISRN Pharm | 2013 | https://conductscience.org/library/papers/24459591 | PubMed |
| 23326192 | Self-microemulsifying drug-delivery system for improved oral bioavailability of pranlukast hemihydrate: preparation and evaluation. | Int J Nanomedicine | 2013 | https://conductscience.org/library/papers/23326192 | PubMed |
| 18852140 | Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18852140 | PubMed |
| 18473177 | Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization. | AAPS PharmSciTech | 2008 | https://conductscience.org/library/papers/18473177 | PubMed |
| 16323952 | Cross-linked polymeric nanogel formulations of 5'-triphosphates of nucleoside analogues: role of the cellular membrane in drug release. | Mol Pharm | 2005 | https://conductscience.org/library/papers/16323952 | PubMed |
| 15906174 | The influence of water content of triglyceride oils on the solubility of steroids. | Pharm Res | 2005 | https://conductscience.org/library/papers/15906174 | PubMed |
| 12162758 | Clinical pharmacokinetics of cytarabine formulations. | Clin Pharmacokinet | 2002 | https://conductscience.org/library/papers/12162758 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8954169
GET https://conductscience.org/api/papers/v1/8954169/authors